Bionovo

From WikiMD's WELLNESSPEDIA

Bionovo Logo

Bionovo, Inc. was a pharmaceutical company focused on the discovery and development of drugs derived from botanical sources. The company was headquartered in Emeryville, California, and was publicly traded on the NASDAQ stock exchange under the ticker symbol BNVI.

History[edit]

Bionovo was founded in 2002 by Dr. Isaac Cohen and Dr. Mary Tagliaferri. The company aimed to develop novel treatments for cancer and women's health, leveraging traditional Chinese medicine and modern scientific techniques.

Research and Development[edit]

Bionovo's research primarily focused on two main areas: oncology and women's health. The company's lead product candidates included:

Menerba[edit]

Menerba was designed to treat menopausal symptoms such as hot flashes and night sweats. It was a selective estrogen receptor beta agonist, which aimed to provide the benefits of estrogen without the associated risks of hormone replacement therapy.

Bezielle[edit]

Bezielle was developed for the treatment of advanced breast cancer. It was derived from a botanical source and aimed to induce cancer cell death without harming normal cells.

Clinical Trials[edit]

Bionovo conducted several clinical trials to evaluate the safety and efficacy of its drug candidates. The company faced challenges in advancing its products through the clinical trial phases, which ultimately impacted its financial stability.

Financial Challenges and Closure[edit]

Despite initial promise, Bionovo struggled with financial difficulties. The company faced challenges in securing sufficient funding to continue its research and development activities. In 2012, Bionovo announced that it was suspending its clinical trials due to a lack of funds. The company eventually ceased operations and filed for bankruptcy.

Legacy[edit]

Bionovo's work contributed to the understanding of botanical sources in drug development, particularly in the areas of oncology and women's health. Although the company did not succeed in bringing its products to market, its research efforts provided valuable insights for future studies.

Related Pages[edit]

Categories[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Bionovo&oldid=5897487"